A novel platform of PEG-only nanocarriers and nanogels has been developed by Rutgers scientists. The nanocarriers can be used from 100Da-100- kDa and are capable of forming stable nanogels and nanogel aggregates in a variety of sizes from 20-30nm up to >1000nm. The carriers and gels have improved solubility over existing technologies and provide for enhanced loading of drug agents. Several methods have been developed to create and tailor a wide variety of polymers and copolymers utilizing an assortment of cross-linkers and functional groups to alter surface charge, charge density, hydrophobicity, cell and tissue interactions and trafficking. Collectively, the characteristics of this novel class of PEG-based nanocarriers, nanogels and nanogel aggregates enable delivery of agents requiring higher dosing and with solubility limitations, and provide for target delivery to the site of action.
- Increased drug loading to overcome conjugation effects of lower potency drugs
- Enhanced local and minimized systemic delivery of drugs, improved solubility of drugs
- PEG is nonimmunogenic and generally regarded as safe
- Drug Delivery
Intellectual Property & Development Status:
- Issued patents: US 9,517,201
- Available for licensing and/or research collaboration